{"id":17335,"date":"2026-06-08T16:05:00","date_gmt":"2026-06-08T14:05:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=aa3cabda2ab81b502deab9bd128ec610"},"modified":"2026-06-08T16:05:00","modified_gmt":"2026-06-08T14:05:00","slug":"seaport-therapeutics-reports-first-quarter-2026-financial-results-and-highlights-recent-corporate-and-clinical-progress","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=17335","title":{"rendered":"Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress"},"content":{"rendered":"<p class=\"bwalignc\">\n<i>New data from Phase 1 trial of GlyphAgo<sup>TM <\/sup>build upon previously reported topline data and further demonstrate GlyphAgo<sup>TM <\/sup>can achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing<\/i><\/p><p class=\"bwalignc\">\n<i>Enrollment in Phase 2b BUOY-1 trial of GlyphAllo<sup>TM <\/sup>is on track with topline data expected in 1H 2027; Seaport dosed first participant in Phase 1 driving simulation trial of GlyphAllo<sup>TM<\/sup>, with data expected in 2H 2026<\/i><\/p><p class=\"bwalignc\">\n<i>Dr. Sharon Mates, Co-Founder, Chair, and CEO of Intra-Cellular Therapies until its acquisition by Johnson &amp; Johnson for $14.6 billion, was appointed to Board of Directors<\/i><\/p><p class=\"bwalignc\">\n<i>Upsized IPO generated $260.0 million in gross proceeds; in addition to $212.6 million on hand as of March 31, 2026, total cash, cash equivalents, and investments expected to fund operations into 2029<\/i><\/p><p>BOSTON--(BUSINESS WIRE)--<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.seaporttx.com&amp;esheet=54548147&amp;newsitemid=20260608629588&amp;lan=en-US&amp;anchor=Seaport+Therapeutics%2C+Inc.&amp;index=1&amp;md5=ae7af43092131a0f262037ba45e5febf\" rel=\"nofollow\" shape=\"rect\">Seaport Therapeutics, Inc.<\/a>, (Nasdaq: SPTX) (\u201cSeaport\u201d or the \u201cCompany\u201d), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced financial results for the first quarter of 2026 and highlighted recent corporate and clinical progress.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260608629588\/en\/2630443\/5\/SEAPORT-LOGO.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260608629588\/en\/2630443\/22\/SEAPORT-LOGO.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260608629588\/en\/2630443\/5\/SEAPORT-LOGO.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260608629588\/en\/2630443\/21\/SEAPORT-LOGO.jpg\" \/><\/a><p>\n\u201cThe first quarter of 2026 was filled with meaningful progress for Seaport, and we significantly advanced the clinical development of our lead GlyphAllo<sup>TM <\/sup>and GlyphAgo<sup>TM <\/sup>programs,\u201d said Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics. \u201cWe previously reported data from the single-ascending dose and crossover portions of the Phase 1 proof-of-concept trial of GlyphAgo<sup>TM<\/sup>, which we believe substantially derisk future clinical development of the program. Today, we announced new multiple-ascending dose data from this trial, which further reinforce the ability of GlyphAgo<sup>TM <\/sup>to achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations. We continue to progress our potentially registration-enabling Phase 2b BUOY-1 trial of GlyphAllo<sup>TM<\/sup> and anticipate topline data from that trial in the first half of next year. With a pipeline of novel programs based on clinically validated mechanisms, an experienced team with a track record of success in neuropsychiatry, and a strong balance sheet bolstered by our recent IPO, we look forward to executing on our mission to transform the treatment of neuropsychiatric disorders and improve patients\u2019 lives.\u201d<\/p><p>\n<b>Recent Business Updates and Anticipated Milestones<\/b><\/p><p>\n<b><i>GlyphAllo<sup>TM <\/sup>(SPT-300 or Glyph Allopregnanolone) Program for Patients with Major Depressive Disorder (MDD)<\/i><\/b><\/p><ul class=\"bwlistdisc\">\n<li>\n<b>Enrollment on Track in Phase 2b BUOY-1 Trial in MDD.<\/b> Seaport is actively enrolling patients in BUOY-1, a two-arm, global, randomized, double-blind, placebo-controlled, potentially registration-enabling Phase 2b trial investigating the safety and efficacy of GlyphAllo<sup>TM <\/sup>in patients with MDD with or without anxious distress. Topline data from the BUOY-1 trial are expected in the first half of 2027. Given the strength in enrollment and to maximize the likelihood that the BUOY-1 trial could be used to support registration, the Company plans to enroll the full prespecified target sample size of approximately 360 patients and no longer intends to perform a sample size re-estimation (SSRE).<\/li>\n<\/ul><ul class=\"bwlistdisc\">\n<li>\n<b>Dosed First Participant in Phase 1 Driving Simulation Trial. <\/b>This randomized, double-blind, placebo-controlled Phase 1 trial is designed to evaluate the potential impact of multiple dose levels of GlyphAllo<sup>TM <\/sup>on simulated driving performance in healthy volunteers. GlyphAllo<sup>TM <\/sup>will be dosed in the evening, and simulated driving performance will be assessed the following morning, approximately nine hours following GlyphAllo<sup>TM<\/sup> administration, as is typical in driving simulation trials. Topline data from the driving simulation trial are expected in the second half of 2026, in advance of the expected topline readout of the BUOY-1 trial.<\/li>\n<\/ul><ul class=\"bwlistdisc\">\n<li>\n<b>Phase 1 and Phase 2a and Preclinical Data Published in <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.science.org%2Fdoi%2F10.1126%2Fscitranslmed.adu2352&amp;esheet=54548147&amp;newsitemid=20260608629588&amp;lan=en-US&amp;anchor=Science+Translational+Medicine&amp;index=2&amp;md5=0448b1740cc29f905e1613dc86bbf519\" rel=\"nofollow\" shape=\"rect\"><i>Science Translational Medicine<\/i><\/a><\/b><i>.<b> <\/b><\/i>This publication details the design, optimization, preclinical evaluation, and Phase 1 and 2a clinical development of GlyphAllo<sup>TM <\/sup>in healthy volunteers. In Phase 1 and 2a trials, GlyphAllo<sup>TM <\/sup>was generally well-tolerated following single- and multiple-ascending oral doses ranging from 70\u20131000 mg, provided dose-dependent, therapeutically relevant plasma exposures of allopregnanolone, demonstrated pharmacodynamic effects in the brain, and potently blunted the acute physiological stress response on a validated clinical model of anxiety.<\/li>\n<\/ul><p>\n<b><i>GlyphAgo<sup>TM <\/sup>(SPT-320 or Glyph Agomelatine) Program for Patients with Generalized Anxiety Disorder (GAD)<\/i><\/b><\/p><ul class=\"bwlistdisc\">\n<li>\n<b>New Data Reported from Multiple-Ascending Dose (MAD) Portion of Phase 1 Proof-of-Concept Trial in Healthy Volunteers<\/b><\/li>\n<\/ul><ul class=\"bwlistcircle bwmarginl2\">\n<li>\nNew data demonstrate that seven-day dosing of GlyphAgo<sup>TM <\/sup>achieved therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing.<\/li>\n<li>\nGlyphAgo<sup>TM <\/sup>AUC<sub>0-24 <\/sub>and Cmax increased dose-dependently over the range of doses studied, and agomelatine exposures following GlyphAgo<sup>TM<\/sup> administration were consistent with data from the single-ascending dose (SAD) and crossover portions of the trial. There was no unmodified agomelatine arm in the MAD portion.<\/li>\n<li>\nRepeat dosing of GlyphAgo<sup>TM <\/sup>confirms favorable safety, tolerability, and pharmacokinetics across the Phase 1 program, with no serious or liver-related adverse events observed.<\/li>\n<li>\nIn April 2026, Seaport reported results from the head-to-head crossover portion of the trial, in which GlyphAgo<sup>TM <\/sup>demonstrated a statistically significant 6.8-fold increase in bioavailability compared to unmodified agomelatine in healthy volunteers, exceeding the program\u2019s two-fold target to mitigate liver exposure. GlyphAgo<sup>TM<\/sup> also showed significantly lower (10-fold) PK variability compared to unmodified agomelatine. The crossover portion included participants who were taking estrogen-containing oral contraceptives that are known to increase agomelatine exposure due to liver drug-drug interaction. In contrast, GlyphAgo<sup>TM<\/sup> exposure was unaffected by oral contraceptives, further supporting the ability of GlyphAgo<sup>TM <\/sup>to bypass first-pass liver metabolism. GlyphAgo<sup>TM <\/sup>demonstrated a 9.6 to 14.5-fold increase in dose-normalized exposure compared to agomelatine in a separate SAD portion of the trial in which no participants were on oral contraceptives. GlyphAgo<sup>TM <\/sup>was well-tolerated across all evaluated doses, and no serious or severe adverse events or liver-related adverse effects were reported.<\/li>\n<li>\nResults support dose selection and planned advancement into two parallel Phase 2 trials in patients with GAD.<\/li>\n<\/ul><ul class=\"bwlistdisc\">\n<li>\n<b>Company Expects to Initiate a Phase 2a Proof-of-Pharmacology Trial in the Second Half of 2026. <\/b>This randomized, double-blind trial of two dose levels of GlyphAgo is designed to demonstrate proof-of-pharmacology by characterizing the potential benefits of GlyphAgo<sup>TM <\/sup>on sleep, including objective measures of sleep architecture, in patients with GAD and sleep disturbance. Topline data from this trial are expected in early 2028.<\/li>\n<\/ul><ul class=\"bwlistdisc\">\n<li>\n<b>Company Expects to Initiate a Phase 2b Trial in the First Half of 2027.<\/b> This randomized, double-blind, placebo-controlled, potentially registration-enabling trial is designed to evaluate the efficacy and safety of GlyphAgo<sup>TM <\/sup>in patients with GAD. Topline data from this trial are expected by year-end 2028.<\/li>\n<\/ul><p>\n<b><i>Preclinical and Discovery Programs<\/i><\/b><\/p><ul class=\"bwlistdisc\">\n<li>\n<b>Glyph2BLSD<sup>TM <\/sup>(SPT-348 or Glyph 2-bromo-LSD) Program on Track.<\/b> Seaport is developing Glyph2BLSD<sup>TM <\/sup>for depressive disorders, including treatment-resistant depression, post-traumatic stress disorder, and headache disorders with significant unmet need. Glyph2BLSD is a non-hallucinogenic neuroplastogen designed to harness the pharmacology of a psychedelic without the hallucination, or \u201ctrip.\u201d Completion of first-in-human-enabling studies is expected by year-end 2027.<\/li>\n<\/ul><ul class=\"bwlistdisc\">\n<li>\n<b>Seaport and Monash Institute of Pharmaceutical Sciences Awarded Up to $15 Million from ARPA-H.<\/b> Advanced Research Projects Agency for Health (ARPA-H) award supports the development of GlyphCele<sup>TM <\/sup>or Cele-Pro<sup>TM<\/sup>, an oral prodrug designed using Seaport\u2019s proprietary Glyph<sup>TM <\/sup>platform to address dysfunctional gut lymphatics and local inflammation linked to metabolic disease and pancreatic cancer.<\/li>\n<\/ul><p>\n<b><i>Corporate<\/i><\/b><\/p><ul class=\"bwlistdisc\">\n<li>\n<b>Upsized IPO Raising $260.0M Completed. <\/b>Seaport closed its upsized initial public offering (IPO) in May 2026, and the Company raised gross proceeds of $260.0 million, before deducting underwriting discounts, commissions, and other offering expenses. The net proceeds from the offering together with the Company\u2019s current cash, cash equivalents and investments are expected to support Seaport\u2019s current operating plans into 2029, which includes multiple anticipated topline data readouts, including the Phase 2b BUOY-1 trial of GlyphAllo<sup>TM <\/sup>in patients with MDD, the Phase 2a trial of GlyphAgo<sup>TM <\/sup>in patients with GAD and sleep disturbance, and the Phase 2b trial of GlyphAgo<sup>TM <\/sup>in patients with GAD.<\/li>\n<\/ul><ul class=\"bwlistdisc\">\n<li>\n<b>Sharon Mates, Ph.D. Appointed to Board of Directors. <\/b>Dr. Mates served as Co-Founder, Chairman, and Chief Executive Officer of Intra-Cellular Therapies, Inc., which she co-founded in 2002, until its acquisition by Johnson &amp; Johnson (J&amp;J) for $14.6 billion in 2025. Under Dr. Mates\u2019 leadership, Intra-Cellular Therapies developed medicines for mental health disorders including bipolar disorder, depression, and schizophrenia, and received U.S. Food and Drug Administration (FDA) approval for its novel antipsychotic CAPLYTA\u00ae, which generated greater than $1.5 billion in sales prior to the company\u2019s acquisition by J&amp;J, and continued its commercial growth thereafter driven by expanded market reach and additional FDA approvals. In connection with Seaport\u2019s IPO, Robert Nelson, Eric Elenko, Ph.D., and Robert Lyne transitioned off of the Company\u2019s Board of Directors.<\/li>\n<\/ul><p>\n<b>First Quarter 2026 Financial Results<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\n<b>Cash Position: <\/b>Cash, cash equivalents, and investments totaled $212.6 million as of March 31, 2026. Subsequent to March 31, 2026, Seaport completed its IPO, in which the Company raised gross proceeds of an additional $260.0 million, before deducting underwriting discounts, commissions, and other offering expenses. Seaport expects its current cash, cash equivalents, and investments to support its current operating plans into 2029.<\/li>\n<\/ul><ul class=\"bwlistdisc\">\n<li>\n<b>R&amp;D Expenses: <\/b>Research and development (R&amp;D) expenses were $21.4 million for the quarter ended March 31, 2026 as compared with $10.5 million for the quarter ended March 31, 2025. The increase in R&amp;D expenses of $10.9 million was primarily due to increases in clinical development expenses of GlyphAllo<sup>TM <\/sup>and GlyphAgo<sup>TM <\/sup>as they advanced into later stage development, and related personnel costs to support the Company\u2019s R&amp;D operations.<\/li>\n<\/ul><ul class=\"bwlistdisc\">\n<li>\n<b>G&amp;A Expenses: <\/b>General and administrative (G&amp;A) expenses were $6.1 million for the quarter ended March 31, 2026 as compared with $5.7 million for the quarter ended March 31, 2025. The increase in G&amp;A expenses of $0.5 million was primarily due to increased personnel costs and was partially offset by reduced professional fees, as compared to the same period in the prior year.<\/li>\n<\/ul><ul class=\"bwlistdisc\">\n<li>\n<b>Net Loss: <\/b>Net loss was $25.4 million for the first quarter of 2026, as compared to a net loss of $13.1 million for the first quarter of 2025.<\/li>\n<\/ul><p>\n<b>About Seaport Therapeutics<\/b><\/p><p>\nSeaport Therapeutics (Nasdaq: SPTX) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through its differentiated approach, the Company identifies clinically validated mechanisms with established efficacy and safety which had historically been limited by high first-pass metabolism, low bioavailability, and\/or side effects. Seaport applies its proprietary Glyph<sup>TM <\/sup>platform to overcome those limitations and invent innovative oral therapies. With an experienced team of industry leaders, Seaport has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. Seaport aims to develop novel, leading treatment options that will make a significant impact for patients and their families. For more information, please visit <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.seaporttx.com%2F&amp;esheet=54548147&amp;newsitemid=20260608629588&amp;lan=en-US&amp;anchor=www.seaporttx.com&amp;index=3&amp;md5=13052b0cbf06affeb5792339a4ea2403\" rel=\"nofollow\" shape=\"rect\">www.seaporttx.com<\/a>.<\/p><p>\n<b>Forward-Looking Statements<\/b><\/p><p>\nThis press release contains \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwould\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding our product candidates, including the ongoing Phase 2b trial of GlyphAllo, enrollment status and anticipated timing of topline data in the first half of 2027, the Phase 1 driving simulation trial for GlyphAllo in healthy volunteers and timing of results in the second half of 2026, the ongoing Phase 1 trial of GlyphAgo, results related thereto, and anticipated Phase 2a proof-of-pharmacology and Phase 2b trials and related data in 2028, preclinical and clinical development activities and timelines, including preclinical and first-in-human-enabling activities for Glyph2BLSD (SPT-348), and our expectations regarding uses of capital, expenses and financial results, including the expected cash runway and financial performance.<\/p><p>\nForward-looking statements are based on management\u2019s current expectations and are subject to risks and uncertainties that could negatively affect Seaport Therapeutics\u2019 business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company\u2019s research and development activities; risks that interim results are not predictive of final results in a clinical trial, Seaport Therapeutics\u2019 ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company\u2019s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; Seaport Therapeutics\u2019 ability to attract, integrate and retain key personnel; risks related to the Company\u2019s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining Seaport Therapeutics\u2019 intellectual property protections; and risks related to the competitive landscape for Seaport Therapeutics\u2019 product candidates; as well as other risks described in \u201cRisk Factors,\u201d in Seaport Therapeutics\u2019 Registration Statement on Form S-1 filed with the Securities and Exchange Commission (SEC), as well as subsequent filings with the SEC. Seaport Therapeutics expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.<\/p><p>\nSeaport uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company\u2019s Investor Relations website, in addition to following the Company\u2019s press releases, SEC filings, public conference calls, presentations, and webcasts.<\/p><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwpadl0 bwalignc\" colspan=\"10\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<b>Seaport Therapeutics, Inc.<\/b><\/p><p class=\"bwcellpmargin bwalignc\">\n<b>Condensed Consolidated Statements of Operations and Comprehensive Loss<\/b><\/p><p class=\"bwcellpmargin bwalignc\">\n<b>(In thousands, except share and per share amounts)<i> (Unaudited)<\/i><\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwvertalignt\" colspan=\"10\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0 bwwidth62\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0\" colspan=\"6\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n<b>Three Months Ended March 31,<\/b><\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0 bwwidth62\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwalignc\" colspan=\"2\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<b>2026<\/b><\/p><\/td><td class=\"bwvertalignb bwpadl0 bwalignc bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwalignc bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwalignc\" colspan=\"2\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<b>2025<\/b><\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl0 bwwidth62\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nOperating expenses:<\/p><\/td><td class=\"bwvertalignt bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"2\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"2\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl3\" colspan=\"2\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nResearch and development (including stock-based compensation expense of\n<br\/>$0.9 million and $0.5 million for three months ended March 31, 2026 and 2025, respectively)<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n$<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwpadr0 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n21,431<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n$<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwpadr0 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n10,534<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl3\" colspan=\"2\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nGeneral and administrative (including stock-based compensation expense of\n<br\/>$1.7 million and $1.1 million for the three months ended March 31, 2026 and 2025, respectively)<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n6,112<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n5,651<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl8 bwwidth62\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nTotal operating expenses<\/p><\/td><td class=\"bwvertalignt bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n27,543<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n16,185<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl0 bwwidth62\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nLoss from operations<\/p><\/td><td class=\"bwvertalignt bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwsinglebottom bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n(27,543<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwsinglebottomtransparent bwpadb3 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignl bwcellpmargin\">\n)<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwsinglebottom bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n(16,185<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwsinglebottomtransparent bwpadb3 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignl bwcellpmargin\">\n)<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth62\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nTotal other income, net<\/p><\/td><td class=\"bwvertalignt bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n2,654<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n3,091<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl0 bwwidth62\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nLoss before income taxes<\/p><\/td><td class=\"bwvertalignt bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n(24,889<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignl bwcellpmargin\">\n)<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n(13,094<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignl bwcellpmargin\">\n)<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth62\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nIncome tax provision<\/p><\/td><td class=\"bwvertalignt bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n519<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n31<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl0 bwwidth62\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nNet loss<\/p><\/td><td class=\"bwvertalignt bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n$<\/p><\/td><td class=\"bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb4 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n(25,408<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwdoublebottomtransparent bwpadb4 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignl bwcellpmargin\">\n)<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n$<\/p><\/td><td class=\"bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb4 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n(13,125<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwdoublebottomtransparent bwpadb4 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignl bwcellpmargin\">\n)<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0 bwwidth62\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0\" colspan=\"2\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0\" colspan=\"2\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl8 bwwidth62\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nNet loss per share, basic and diluted<\/p><\/td><td class=\"bwvertalignt bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n$<\/p><\/td><td class=\"bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb4 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n(10.34<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwdoublebottomtransparent bwpadb4 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignl bwcellpmargin\">\n)<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n$<\/p><\/td><td class=\"bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb4 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n(5.65<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwdoublebottomtransparent bwpadb4 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignl bwcellpmargin\">\n)<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl8 bwwidth62\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nWeighted-average common shares outstanding, basic and diluted<\/p><\/td><td class=\"bwvertalignt bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwdoublebottom bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwdoublebottom bwpadl0 bwpadr0 bwpadb4 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n2,456,766<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwdoublebottom bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwdoublebottom bwpadl0 bwpadr0 bwpadb4 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n2,323,724<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<\/table><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwpadl0\" colspan=\"9\" rowspan=\"1\"\/>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwalignc\" colspan=\"9\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<b>Seaport Therapeutics, Inc.<\/b><\/p><p class=\"bwcellpmargin bwalignc\">\n<b>Selected Condensed Consolidated Balance Sheet Data<\/b><\/p><p class=\"bwcellpmargin bwalignc\">\n<b>(In thousands) <i>(Unaudited)<\/i><\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwvertalignt\" colspan=\"9\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0 bwwidth64\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0\" colspan=\"2\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n<b>March 31,<\/b><\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0\" colspan=\"2\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n<b>December 31,<\/b><\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0 bwwidth64\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwalignc\" colspan=\"2\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<b>2026<\/b><\/p><\/td><td class=\"bwvertalignb bwpadl0 bwalignc bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwalignc bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwalignc\" colspan=\"2\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<b>2025<\/b><\/p><\/td><td class=\"bwvertalignb bwpadl0 bwalignc bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth64\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nCash, cash equivalents and investments<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n$<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n212,642<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n$<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n233,653<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0 bwwidth64\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nWorking capital<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n$<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwpadr0 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n174,118<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n$<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwpadr0 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n210,448<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth64\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nTotal assets<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n$<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n227,673<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n$<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n249,009<\/p><\/td><td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0 bwwidth64\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nTotal stockholders' deficit<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n$<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwpadr0 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n(115,621<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignl bwcellpmargin\">\n)<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n$<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwpadr0 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n(92,545<\/p><\/td><td class=\"bwvertalignb bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignl bwcellpmargin\">\n)<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwvertalignt\" colspan=\"9\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"9\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nThe above balance sheet data do not reflect the Company\u2019s upsized initial public offering (IPO) in May 2026. In the IPO, the Company raised gross proceeds of $260.0 million, before deducting underwriting discounts, commissions, and other offering expenses.<\/p><\/td><\/tr>\n<\/table><p>\n\u00a0<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>Seaport Therapeutics\n<br\/>Media Contact:\n<br\/><\/b>Shannon Costello\n<br\/>Vice President, Communications\n<br\/><a  href=\"mailto:publicrelations@seaporttx.com\" rel=\"nofollow\" shape=\"rect\">publicrelations@seaporttx.com<\/a><br\/>\n<br\/><b>Investor Contact:\n<br\/><\/b>Adam Bero, Ph.D.\n<br\/>Head of Investor Relations\n<br\/><a  href=\"mailto:ir@seaporttx.com\" rel=\"nofollow\" shape=\"rect\">ir@seaporttx.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>New data from Phase 1 trial of GlyphAgoTM build upon previously reported topline data and further demonstrate GlyphAgoTM can achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eliminate the n&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-17335","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/17335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17335"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/17335\/revisions"}],"predecessor-version":[{"id":17336,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/17335\/revisions\/17336"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}